Scholarlink

<p>Doxorubicin (DOX) has been used in the treatment of various malignant tumors, including cervical cancer. However, the application of DOX is seriously hampered by the side effects, especially the cardiotoxicity, hepatotoxicity and nephrotoxicity. Sodium new houttuyfonate (SNH), a structurally modified derivative of <i>Houttuynia cordata Thunb</i>., possesses anti-tumor and anti-inflammatory activity. This study designed an SNH and DOX co-loaded liposome (SNH@DOX Lipos) to deliver the two drugs within tumor cells and reduce DOX induced systemic toxicity. The results indicated that SNH@DOX Lipos had an average size of 136.1 ± 2.24&#xa0;nm with a PDI of 0.236 ± 0.03. The encapsulation efficiency of either SNH or DOX was more than 80%. Further study clarified that preferential release of SNH@DOX Lipos contributed to facilitating greater accumulation of drugs within the tumors. The combination of free SNH and DOX exerted a synergistic anti-cervical cancer effect. Moreover, SNH@DOX Lipos enhanced anti-cervical cancer efficacy and induced cell apoptosis <i>via</i> the TNF-α/RIP1/NF-κB signaling pathway. Also, SNH@DOX Lipos decreased the secretion of IL-6 and TNF-α in heart tissue and the serum ALT, AST and BUN levels, reducing systemic toxicity caused by DOX. Therefore, SNH@DOX Lipos may have promising prospects for the treatment of cervical cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sodium new houttuyfonate and doxorubicin co-loaded liposomes for the treatment of cervical cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月21日

查看全文
  • Zhuangli Zhang,
  • Jiayi Chen,
  • Yueyue Wu,
  • Yaxin Zhao,
  • Jiaqi Wang,
  • Mengxu Pan,
  • Adan Liu,
  • Yarong Wang,
  • Jianbo Li,
  • Xiuxia Wang,
  • Na Li,
  • Jian Wang,
  • Xinyu Kang,
  • Yue Tang,
  • Yaoxin Wang,
  • Youmei Peng

摘要

Doxorubicin (DOX) has been used in the treatment of various malignant tumors, including cervical cancer. However, the application of DOX is seriously hampered by the side effects, especially the cardiotoxicity, hepatotoxicity and nephrotoxicity. Sodium new houttuyfonate (SNH), a structurally modified derivative of Houttuynia cordata Thunb., possesses anti-tumor and anti-inflammatory activity. This study designed an SNH and DOX co-loaded liposome (SNH@DOX Lipos) to deliver the two drugs within tumor cells and reduce DOX induced systemic toxicity. The results indicated that SNH@DOX Lipos had an average size of 136.1 ± 2.24 nm with a PDI of 0.236 ± 0.03. The encapsulation efficiency of either SNH or DOX was more than 80%. Further study clarified that preferential release of SNH@DOX Lipos contributed to facilitating greater accumulation of drugs within the tumors. The combination of free SNH and DOX exerted a synergistic anti-cervical cancer effect. Moreover, SNH@DOX Lipos enhanced anti-cervical cancer efficacy and induced cell apoptosis via the TNF-α/RIP1/NF-κB signaling pathway. Also, SNH@DOX Lipos decreased the secretion of IL-6 and TNF-α in heart tissue and the serum ALT, AST and BUN levels, reducing systemic toxicity caused by DOX. Therefore, SNH@DOX Lipos may have promising prospects for the treatment of cervical cancer.